Marcie Qian

Senior Director
15+ years of experience providing tax advisory services
Familiar with taxes in the PRC
Extensive experience with M&A tax advisory services
Shanghai
@alvarezmarsal
LinkedIn
Copied!
Marcie Qian is a Senior Director with Alvarez & Marsal Tax in Shanghai. She specializes in China tax advisory and compliance.

Ms. Qian is familiar with the tax environment in the People’s Republic of China (PRC) and has over 15 years of experience providing tax advisory services to private equity funds, multinational corporations and domestic companies. She provides M&A tax advisory services, including tax due diligence, tax structuring, tax model review, transaction documentation review and deal negotiations.

Ms. Qian also provides general tax advice and tax compliance for both corporate clients and individuals. She has worked with clients in various industries, including manufacturing, real estate, technology, media, and telecom (TMT), retail, automotive, chemicals and pharmaceuticals.

Prior to joining A&M, Ms. Qian worked in EY Shanghai for 12 years in the business tax advisory group and transaction tax group.

Ms. Qian also worked on tax structuring and post-deal group reorganization. She provided PRC tax due diligence and tax structuring advice to private equity funds investing in Chinese properties, and advised domestic groups with outbound investments in global companies in other jurisdictions.

Ms. Qian earned a bachelor's degree in money and banking from Shanghai International Studies University. She is a member of CPA Australia and a China Certified Tax Agent. 

 

Insights By This Professional

The draft revision of the PRC Tax Collection and Administration Law is open for public consultation through 27 April 2025.
Latest insights The latest insights from Marcie Qian's team
Thought Leadership
Effective July 31, 2026, the additional Section 232 tariff on patented pharmaceuticals that are products of the United Kingdom was reduced from 10% to zero (heading 9903.04.63), implementing the U.S.–UK Pharmaceutical Pricing Arrangement. Because UK patented pharmaceuticals remain subject to Section 232 (at a 0% rate), they also fall within the Section 232 carve-out from the new Section 301 forced labor tariffs — so qualifying UK patented product should face no additional duty under either regime.